Cannabinoids Used for Medical Purposes in Children and Adolescents

Cannabinoids Used for Medical Purposes in Children and Adolescents

Authors

  • A.Phillips California Northstate University College of Medicine
  • A.Malik California Northstate University College of Medicine

Keywords:

Cannabinoids, Medical Purposes, Children and Adolescents

Abstract

Background: The literature on the use of cannabinoids for medical purposes in children and adolescents presents a complex landscape of potential benefits, challenges, and gaps in research. The introduction highlights a growing interest in cannabinoids, particularly for conditions such as refractory epilepsy, pain management, and palliative care. Literature Review: (Ben-Zeev, 2010) critically discusses the role of cannabidiol (CBD) in managing refractory epilepsy, emphasizing the importance of distinguishing between artisanal cannabis and FDA-approved formulations like Epidiolex®. The need for larger clinical trials is echoed by (Raucci et al., 2010) who call for double-blinded placebo-controlled studies to better understand CBD's pharmacokinetics and safety profile. Similarly, explore the efficacy of cannabinoids in treating spasticity in children with cerebral palsy, demonstrating promising results but also stressing the necessity for comprehensive safety evaluations. (Cassa Macedo et al., 2010) highlight the challenges posed by misinformation surrounding medical cannabis, which can lead to unrealistic expectations among families. This sentiment is further supported by (J Woo et al., 2010) who report variability in pain relief outcomes among pediatric patients using cannabinoids, underscoring the need for more robust comparative studies to guide treatment decisions. Conclusion: Overall, the literature indicates a cautious but growing interest in the therapeutic use of cannabinoids in pediatric medicine. While there are promising findings regarding their potential benefits, particularly in managing specific conditions like epilepsy and spasticity, the overarching consensus is that further research is essential to establish clear guidelines and safety profiles. The variability in patient responses and the potential risks associated with cannabinoid use necessitate a careful, evidence-based approach to treatment in this vulnerable population.

Downloads

Published

2017-01-23